HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Groups Shine Light On “Helps Prevent” Claim In Sunscreen Comments

This article was originally published in The Tan Sheet

Executive Summary

Sunscreen labeling that claims the product "helps prevent" premature skin aging, cancer and other damage does not suggest sunscreen alone protects against these conditions, but in fact informs consumers that "complementary measures" are needed for adequate protection, according to trade groups' comments on FDA's proposal to amend the sunscreen final monograph

You may also be interested in...



Sunscreen Rule Will Cost Four Times FDA’s Prediction, Industry Tells OMB

FDA's low-ball estimate of the cost to industry from the final OTC sunscreen monograph – a quarter of the amount manufacturers anticipate – relieved the agency from having to submit a full account of its rulemaking to the Office of Management and Budget, Energizer Holdings suggests.

Sunscreen Study Should Sway FDA To Lift Cap On SPF Labeling - J&J

Johnson & Johnson adds data from research comparing two sunscreen formulations to its argument against a proposed cap on sun protection factors allowed on product labeling under FDA's pending final sunscreen monograph

FDA Nonprescription Office Adding Staff To Focus On Monograph Work

FDA's Division of Nonprescription Regulation Development will hire additional staff to accelerate monograph work and enhance the office's internal expertise

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel